{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:46:39Z","timestamp":1792424799376,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T00:00:00Z","timestamp":1462147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40262-016-0396-1","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T14:28:24Z","timestamp":1462199304000},"page":"1295-1335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?"],"prefix":"10.1007","volume":"55","author":[{"given":"Emily","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Tett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Isbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,2]]},"reference":[{"issue":"10","key":"396_CR1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40262-015-0282-2","volume":"54","author":"C Staatz","year":"2015","unstructured":"Staatz C, Tett SE. Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin Pharmacokinet. 2015;54(10):993\u20131025.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"396_CR2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14622416.6.4.323","volume":"6","author":"D Hesselink","year":"2005","unstructured":"Hesselink D, van Gelder T, van Schaik R. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualised immunosuppression. Pharmacogenomics. 2005;6(4):323\u201337.","journal-title":"Pharmacogenomics."},{"issue":"10","key":"396_CR3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"C Staatz","year":"2004","unstructured":"Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamis of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"396_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","volume":"29","author":"N Shuker","year":"2015","unstructured":"Shuker N, van Gelder T, Hesselink A. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev. 2015;29(2):78\u201384.","journal-title":"Transplant Rev."},{"issue":"12","key":"396_CR5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","volume":"63","author":"L Scott","year":"2000","unstructured":"Scott L, McKeage K, Keam S, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2000;63(12):1247\u201397.","journal-title":"Drugs."},{"issue":"5","key":"396_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/TP.0b013e3181e9feda","volume":"90","author":"H Jonge de","year":"2010","unstructured":"de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C 0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation. 2010;90(5):523\u20139.","journal-title":"Transplantation"},{"issue":"2","key":"396_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","volume":"31","author":"P Wallemacq","year":"2009","unstructured":"Wallemacq P, Armstrong V, Brrunet M, et al. Opportunities to optimise tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit. 2009;31(2):139\u201352.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"396_CR8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","volume":"62","author":"D Laskow","year":"1996","unstructured":"Laskow D, Vincenti F, Neylan J, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation. Transplantation. 1996;62(7):900\u20135.","journal-title":"Transplantation"},{"issue":"7","key":"396_CR9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","volume":"62","author":"R Kershner","year":"1996","unstructured":"Kershner R, Fitzsimmons W. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62(7):920\u20136.","journal-title":"Transplantation"},{"issue":"3","key":"396_CR10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0b013e318285e779","volume":"35","author":"F Saint-Marcoux","year":"2013","unstructured":"Saint-Marcoux F, Woillard J, Jurado C, et al. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit. 2013;35(3):322\u20137.","journal-title":"Ther Drug Monit"},{"key":"396_CR11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/00912700122010429","volume":"41","author":"R Venkataramanan","year":"2001","unstructured":"Venkataramanan R, Shaw L, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41:542\u201351.","journal-title":"J Clin Pharmacol"},{"key":"396_CR12","first-page":"4445","volume":"48","author":"Y Bottiger","year":"1998","unstructured":"Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1998;48:4445\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"396_CR13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/ndt\/16.9.1905","volume":"16","author":"C Staatz","year":"2001","unstructured":"Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"396_CR14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0041-1345(98)01633-9","volume":"31","author":"N Undre","year":"1999","unstructured":"Undre N, Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296\u20138.","journal-title":"Transplant Proc."},{"issue":"4","key":"396_CR15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/clpt.2014.140","volume":"96","author":"Z Daher Abdi","year":"2014","unstructured":"Daher Abdi Z, Premaud A, Essig M, et al. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. Clin Pharmacol Ther. 2014;96(4):508\u201315.","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"396_CR16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","volume":"13","author":"R Bouamar","year":"2013","unstructured":"Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(dagger). Am J Transplant. 2013;13(5):1253\u201361.","journal-title":"Am J Transplant"},{"issue":"6","key":"396_CR17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1600-6143.2005.00870.x","volume":"5","author":"C Knoop","year":"2005","unstructured":"Knoop C, Thiry P, Saint-Marcoux F, et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant. 2005;5(6):1477\u201382.","journal-title":"Am J Transplant"},{"issue":"4","key":"396_CR18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(00)70013-8","volume":"35","author":"K Wong","year":"2000","unstructured":"Wong K, Shek C, Chau K, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35(4):660\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"396_CR19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.ftd.0000211810.19935.44","volume":"28","author":"L Ting","year":"2006","unstructured":"Ting L, Villeneuve E, Ensom M. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28(3):419\u201330.","journal-title":"Ther Drug Monit"},{"key":"396_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","volume":"33","author":"A van Der meer","year":"2011","unstructured":"van Der meer A, Marcus M, Touw D, et al. Optimal sampling strategy development methodology using Maximum A Posteriori Bayesian estimation. Ther Drug Monit. 2011;33:133\u201346.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"396_CR21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/11596380-000000000-00000","volume":"50","author":"C Staatz","year":"2011","unstructured":"Staatz C, Tett S. Maximum A Posteriori Bayesian estimation of mycophenolic acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2011;50(12):759\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"396_CR22","volume-title":"NONMEM user\u2019s\u00a0guides (1989\u20132009)","author":"A Beal","year":"2009","unstructured":"Beal A, Sheiner LB, Boeckmann A, et al. NONMEM user\u2019s\u00a0guides (1989\u20132009). Ellicott City: Icon Development Solutions; 2009."},{"issue":"1","key":"396_CR23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E Storset","year":"2014","unstructured":"Storset E, Holford N, Midtvedt K, et al. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70(1):65\u201377.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"396_CR24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/17425255.2015.1033397","volume":"11","author":"LM Andrews","year":"2015","unstructured":"Andrews LM, Riva N, de Winter BC, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol. 2015;11(6):921\u201336.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"3","key":"396_CR25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","volume":"71","author":"J Woillard","year":"2011","unstructured":"Woillard J, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations\u2013twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71(3):391\u2013402.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"396_CR26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/bcp.12007","volume":"75","author":"F Musuamba","year":"2013","unstructured":"Musuamba F, Mourad M, Haufroid V, et al. Statistical tools for dose individualisation of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. Br J Clin Pharmacol. 2013;75(5):1277\u201388.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"396_CR27","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/0091270011423661","volume":"52","author":"F Musuamba","year":"2012","unstructured":"Musuamba F, Mourad M, Haufroid V, et al. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol. 2012;52(12):1833\u201343.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"396_CR28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.5414\/CP202152","volume":"53","author":"JLS Zhang","year":"2015","unstructured":"Zhang JLS, Xue L, Ding X, Zhang H, Miao L. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2015;53(9):728\u201336.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5\u20136","key":"396_CR29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","volume":"61","author":"M Antignac","year":"2005","unstructured":"Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005;61(5\u20136):409\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"396_CR30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1592\/phco.26.8.1069","volume":"26","author":"J Lee","year":"2006","unstructured":"Lee J, Hahn H, Son I, et al. Factors affecting the apparent clearance of tacrolimus in korean adult liver transplant recipients. Pharmacotherapy. 2006;26(8):1069\u201377.","journal-title":"Pharmacotherapy."},{"issue":"9","key":"396_CR31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","volume":"45","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang J, Zhang Y, et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica. 2015;45(9):840\u20136.","journal-title":"Xenobiotica"},{"issue":"1","key":"396_CR32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bcp.12174","volume":"77","author":"M Jalil","year":"2014","unstructured":"Jalil M, Hawwa AF, McKiernan PJ, et al. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Br J Clin Pharmacol. 2014;77(1):130\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"396_CR33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bcp.12276","volume":"77","author":"N Kassir","year":"2014","unstructured":"Kassir N, Labb\u00e9 L, Delaloye J, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. Br J Clin Pharmacol. 2014;77(6):1051\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"396_CR34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003088-200544120-00010","volume":"44","author":"F Saint-Marcoux","year":"2005","unstructured":"Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet. 2005;44(12):1317\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"396_CR35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003088-200443110-00005","volume":"43","author":"D Kuypers","year":"2004","unstructured":"Kuypers D, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids\u2014a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43(11):741\u201362.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"396_CR36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bcp.12703","volume":"80","author":"H Jonge de","year":"2015","unstructured":"de Jonge H, Vanhove T, de Loor H, et al. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol. 2015;80(3):548\u201359.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"396_CR37","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1111\/j.1600-6143.2012.04232.x","volume":"12","author":"PA Jacobson","year":"2012","unstructured":"Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326\u201336.","journal-title":"Am J Transplant"},{"issue":"9","key":"396_CR38","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/ndt\/gfr253","volume":"26","author":"F Glowacki","year":"2011","unstructured":"Glowacki F, Lionet A, Buob D, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 2011;26(9):3046\u201350.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"396_CR39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","volume":"23","author":"J Barbarino","year":"2013","unstructured":"Barbarino J, Staatz C, Venkataramanan R, et al. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563\u201385.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"396_CR40","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2217\/pgs.13.89","volume":"14","author":"M Kurzawski","year":"2013","unstructured":"Kurzawski M, Dro\u017adzik M. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. Pharmacogenomics. 2013;14(9):1099\u2013118.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"396_CR41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1517\/17425255.2011.570260","volume":"7","author":"N Picard","year":"2011","unstructured":"Picard N, Marquet P. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol. 2011;7(6):731\u201343.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"396_CR42","doi-asserted-by":"crossref","first-page":"e91555","DOI":"10.1371\/journal.pone.0091555","volume":"9","author":"G Dessilly","year":"2014","unstructured":"Dessilly G, Elens L, Panin N, et al. ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One. 2014;9(3):e91555.","journal-title":"PLoS One"},{"issue":"6","key":"396_CR43","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/bcp.12747","volume":"80","author":"K Monostory","year":"2015","unstructured":"Monostory K, Toth K, Kiss A, et al. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. Br J Clin Pharmacol. 2015;80(6):1429\u201337.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"396_CR44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2217\/pgs.15.42","volume":"16","author":"R Pulk","year":"2015","unstructured":"Pulk R, Schlad D, Oetting W, et al. Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics. 2015;16(8):841\u201354.","journal-title":"Pharmacogenomics."},{"issue":"3","key":"396_CR45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2133\/dmpk.DMPK-12-SH-093","volume":"28","author":"A Boivin","year":"2013","unstructured":"Boivin A, Cardinal H, Barama A, et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug Metab Pharmacokinet. 2013;28(3):274\u20137.","journal-title":"Drug Metab Pharmacokinet"},{"key":"396_CR46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0b013e31816babef","volume":"30","author":"E Thervet","year":"2008","unstructured":"Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008;30:143\u201350.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"396_CR47","first-page":"721","volume":"87","author":"E Thervet","year":"2010","unstructured":"Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"396_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13691","author":"N Shuker","year":"2015","unstructured":"Shuker N, Bouamar R, van Schaik RH, et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2015;. doi: 10.1111\/ajt.13691 (Epub 2015 Dec 29).","journal-title":"Am J Transplant"},{"issue":"5","key":"396_CR49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31826aabc3","volume":"34","author":"N Holford","year":"2012","unstructured":"Holford N, Buclin T. Safe and effective variability\u2014a criterion for dose individualization. Ther Drug Monit. 2012;34(5):565\u20138.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"396_CR50","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","volume":"9","author":"H Ekberg","year":"2009","unstructured":"Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3\u00a0years after transplantation. Am J Transplant. 2009;9(8):1876\u201385.","journal-title":"Am J Transplant"},{"issue":"1","key":"396_CR51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","volume":"21","author":"N Lent-Evers van","year":"1999","unstructured":"van Lent-Evers N, Mathot R, Geus W, et al. Impact of goal-orientated and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21(1):63\u201373.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"396_CR52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","volume":"338","author":"W Evans","year":"1998","unstructured":"Evans W, Relling MV, Rodman J, et al. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia. N Engl J Med. 1998;338(8):499\u2013505.","journal-title":"N Engl J Med"},{"key":"396_CR53","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","volume":"99","author":"E Storset","year":"2015","unstructured":"Storset E, Asberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, randomized study. Transplantation. 2015;99:2158\u201366.","journal-title":"Transplantation."},{"key":"396_CR54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1681\/ASN.V131221","volume":"13","author":"J Boots","year":"2002","unstructured":"Boots J, Van Duijnhoven E, Christiaans M, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"396_CR55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.tp.0000251807.72246.7d","volume":"83","author":"F Cosio","year":"2007","unstructured":"Cosio F, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83(4):411\u20136.","journal-title":"Transplantation"},{"issue":"6","key":"396_CR56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clinbiochem.2014.12.018","volume":"48","author":"F Lemaitre","year":"2015","unstructured":"Lemaitre F, Blanchet B, Latournerie M, et al. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clin Biochem. 2015;48(6):406\u201311.","journal-title":"Clin Biochem"},{"key":"396_CR57","unstructured":"Barraclough K, Staatz C, Isbel N. Pharmacokinetic, pharmacogenetic and pharmacodynamic monitoring of tacrolimus, mycophenolate and oral corticosteroids in adult kidney transplantation. In: Lim WH, editor. The complex evolution of kidney transplantation: pre-transplant donor and recipient assessment, transplant surgery, immunosuppression, high risk transplants and management of post transplant complications. Organ Transplant Research Horizons; Renal and Urologic Disorders. New York: Nova Science Publisher; 2014. p. 185\u2013261."},{"issue":"1","key":"396_CR58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","volume":"52","author":"A Fuchs","year":"2013","unstructured":"Fuchs A, Csajka C, Thoma Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"396_CR59","unstructured":"Pharmacology LUHLo. ImmunoSuppressants Bayesian dose Adjustment (ISBA). Limoges; 2005. https:\/\/pharmaco.chu-limoges.fr . Accessed 4 Apr 2016."},{"issue":"2","key":"396_CR60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2125.2010.03815.x","volume":"71","author":"K Barraclough","year":"2011","unstructured":"Barraclough K, Isbel NM, Kirkpatrick CM, et al. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol. 2011;71(2):207\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"396_CR61","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","volume":"48","author":"K Benkali","year":"2009","unstructured":"Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48(12):805\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"396_CR62","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","volume":"49","author":"K Benkali","year":"2010","unstructured":"Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010;49(10):683\u201392.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"396_CR63","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02888.x","volume":"64","author":"M Antignac","year":"2007","unstructured":"Antignac M, Barrou B, Farinotti R, et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64(6):750\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"396_CR64","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","volume":"67","author":"E Scholten","year":"2005","unstructured":"Scholten E, Cremers S, Schoemaker R, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440\u20137.","journal-title":"Kidney Int"},{"issue":"6","key":"396_CR65","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1067\/mcp.2002.129304","volume":"72","author":"C Staatz","year":"2002","unstructured":"Staatz C, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72(6):660\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"396_CR66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0b013e3181cc70db","volume":"32","author":"F Saint-Marcoux","year":"2010","unstructured":"Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit. 2010;32(2):129\u201335.","journal-title":"Ther Drug Monit"},{"key":"396_CR67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","volume":"31","author":"R Press","year":"2009","unstructured":"Press R, Ploeger B, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187\u201397.","journal-title":"Ther Drug Monit"},{"key":"396_CR68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/FTD.0b013e31821633a6","volume":"33","author":"F Saint-Marcoux","year":"2011","unstructured":"Saint-Marcoux F, Debord J, Parant F, et al. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. Ther Drug Monit. 2011;33:171\u20137.","journal-title":"Ther Drug Monit."},{"issue":"6","key":"396_CR69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5414\/CPP48375","volume":"48","author":"R Velickovic-Radovanovic","year":"2010","unstructured":"Velickovic-Radovanovic R, Catic-Djordjevic A, Milovanovic J, et al. Population pharmacokinetics of tacrolimus in kidney transplant patients. Int J Clin Pharmacol Ther. 2010;48(6):375\u201382.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"396_CR70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00228-012-1296-4","volume":"69","author":"N Han","year":"2013","unstructured":"Han N, Yun HY, Hong JY, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53\u201363.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"396_CR71","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40262-013-0069-2","volume":"52","author":"K Ogasawara","year":"2013","unstructured":"Ogasawara K, Chitnis S, Gohh R, et al. Multidrug resistance-associated protein 2 (MRP2\/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52(9):751\u201362.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"396_CR72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","volume":"23","author":"X Zuo","year":"2013","unstructured":"Zuo X, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom. 2013;23(5):251\u201361.","journal-title":"Pharmacogenet Genom."},{"issue":"2","key":"396_CR73","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/FTD.0000000000000134","volume":"37","author":"F Andreu","year":"2015","unstructured":"Andreu F, Colom H, Grinyo J, et al. Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit. 2015;37(2):246\u201355.","journal-title":"Ther Drug Monit"},{"key":"396_CR74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"T Bergmann","year":"2014","unstructured":"Bergmann T, Hennig S, Barraclough K, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36:62\u201370.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"396_CR75","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/tri.12194","volume":"26","author":"A Asberg","year":"2013","unstructured":"Asberg A, Midtvedt K, van Guilder M, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transplant Int. 2013;26(12):1198\u2013207.","journal-title":"Transplant Int."},{"key":"396_CR76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejps.2013.10.008","volume":"52","author":"B Golubovic","year":"2014","unstructured":"Golubovic B, Vucicevic K, Radivojevic D, et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients\u2013population pharmacokinetic approach. Eur J Pharm Sci. 2014;52:34\u201340.","journal-title":"Eur J Pharm Sci"},{"key":"396_CR77","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bcpt.12176","volume":"114","author":"N Han","year":"2014","unstructured":"Han N, Ha S, Yun H, et al. Population pharmacokinetic\u2013pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 2014;114:400\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"396_CR78","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/clpt.2009.210","volume":"86","author":"W Zhao","year":"2009","unstructured":"Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609\u201318.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"396_CR79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00228-012-1330-6","volume":"69","author":"W Zhao","year":"2013","unstructured":"Zhao W, Fakhoury M, Baudouin V, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(2):189\u201395.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"396_CR80","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bcp.12649","volume":"80","author":"C Jacobo-Cabral","year":"2015","unstructured":"Jacobo-Cabral C, Garcia-Roca P, Romero-Tejeda EM, et al. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. Br J Clin Pharmacol. 2015;80(4):630\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"396_CR81","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/jlts.2003.50023","volume":"9","author":"C Staatz","year":"2003","unstructured":"Staatz C, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9(2):130\u20137.","journal-title":"Liver Transpl"},{"issue":"2","key":"396_CR82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00007691-200104000-00006","volume":"23","author":"M Macchi-Andanson","year":"2001","unstructured":"Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit. 2001;23(2):129\u201333.","journal-title":"Ther Drug Monit"},{"issue":"6\u20137","key":"396_CR83","first-page":"479","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6\u20137):479\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"13","key":"396_CR84","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/00003088-200342130-00006","volume":"42","author":"M Fukudo","year":"2003","unstructured":"Fukudo M, Yano I, Fukatsu S, et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 2003;42(13):1161.","journal-title":"Clin Pharmacokinet"},{"key":"396_CR85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/01.ftd.0000170029.36573.a0","volume":"27","author":"H Zahir","year":"2005","unstructured":"Zahir H, McLachlan A, Nelson A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit. 2005;27:422\u201330.","journal-title":"Ther Drug Monit"},{"key":"396_CR86","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Lu W, Zhua J, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007;32:505\u201315.","journal-title":"J Clin Pharm Ther"},{"key":"396_CR87","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/FTD.0b013e318178e31b","volume":"30","author":"B Blanchet","year":"2008","unstructured":"Blanchet B, Duvoux C, Costentin C, et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit. 2008;30:412\u20138.","journal-title":"Ther Drug Monit"},{"key":"396_CR88","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FTD.0b013e31824a67eb","volume":"34","author":"X Zhang","year":"2012","unstructured":"Zhang X, Wang Z, Fan J, et al. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. Ther Drug Monit. 2012;34:126\u201333.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"396_CR89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-012-1300-z","volume":"69","author":"I Oteo","year":"2013","unstructured":"Oteo I, Lukas JC, Leal N, et al. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol. 2013;69(1):65\u201374.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"396_CR90","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5414\/CP201800","volume":"51","author":"N Valdivieso","year":"2013","unstructured":"Valdivieso N, Oteo I, Valdivieso A, et al. Tacrolimus dose individualization in \u201cde novo\u201d patients after 10\u00a0years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. Int J Clin Pharmacol Ther. 2013;51(7):606\u201314.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"396_CR91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200645010-00004","volume":"45","author":"W Sam","year":"2006","unstructured":"Sam W, Tham L, Holmes M, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet. 2006;45(1):59\u201375.","journal-title":"Clin Pharmacokinet"},{"key":"396_CR92","doi-asserted-by":"publisher","first-page":"713650","DOI":"10.1155\/2014\/713650","volume":"2014","author":"L Zhu","year":"2014","unstructured":"Zhu L, Wang H, Sun X, et al. The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm. 2014;2014:713650. doi: 10.1155\/2014\/713650","journal-title":"J Pharm"},{"issue":"2","key":"396_CR93","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJ Moes","year":"2016","unstructured":"Moes DJ, van der Bent SA, Swen JJ, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016;72(2):163\u201374.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"396_CR94","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/aps.2014.110","volume":"36","author":"YX Lu","year":"2015","unstructured":"Lu YX, Su QH, Wu KH, et al. A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin. 2015;36(2):281\u20138.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"396_CR95","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","volume":"33","author":"J Wallin","year":"2011","unstructured":"Wallin J, Bergstrand M, Wilczek HE, et al. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit. 2011;33(6):663\u201372.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"396_CR96","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200109270-00013","volume":"72","author":"C Staatz","year":"2001","unstructured":"Staatz C, Taylor P, Lynch S, et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation. 2001;72(6):1051\u201361.","journal-title":"Transplantation"},{"key":"396_CR97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2125.2000.00288.x","volume":"50","author":"W Sam","year":"2000","unstructured":"Sam W, Aw M, Quak H, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol. 2000;50:531\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"396_CR98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003088-200140010-00005","volume":"40","author":"M Sanchez","year":"2001","unstructured":"Sanchez M, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet. 2001;40(1):63\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"396_CR99","first-page":"1108","volume":"27","author":"M Yasuhara","year":"1995","unstructured":"Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc. 1995;27(1):1108\u201310.","journal-title":"Transplant Proc."},{"issue":"8","key":"396_CR100","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","volume":"69","author":"V Guy-Viterbo","year":"2013","unstructured":"Guy-Viterbo V, Scohy A, Verbeeck RK, et al. Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol. 2013;69(8):1533\u201342.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"396_CR101","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","volume":"80","author":"M Fukudo","year":"2006","unstructured":"Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006;80(4):331\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"396_CR102","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/pgs.14.75","volume":"15","author":"V Guy-Viterbo","year":"2014","unstructured":"Guy-Viterbo V, Baudet H, Elens L, et al. Influence of donor\u2013recipient CYP3A4\/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics. 2014;15(9):1207\u201321.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"396_CR103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","volume":"36","author":"F Musuamba","year":"2014","unstructured":"Musuamba F, Guy-Viterbo V, Reding R, et al. Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit. 2014;36(1):54\u201361.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"396_CR104","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5414\/CP202189","volume":"53","author":"J Yang","year":"2015","unstructured":"Yang J, Liao SS, Zhu LQ, et al. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther. 2015;53(1):75\u201383.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"396_CR105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","volume":"51","author":"C Monchaud","year":"2012","unstructured":"Monchaud C, de Winter BC, Knoop C, et al. Population pharmacokinetic modelling and design of a bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 2012;51(3):175\u201386.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"396_CR106","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00228-007-0354-9","volume":"63","author":"R Op den Buijsch","year":"2007","unstructured":"Op den Buijsch R, van de Plas A, Stolk L, et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol. 2007;63(11):1039\u201344.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"396_CR107","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FTD.0b013e318235d067","volume":"33","author":"W Zhao","year":"2011","unstructured":"Zhao W, Fakhoury M, Baudouin V, et al. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. Ther Drug Monit. 2011;33(6):681\u20137.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"396_CR108","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-012-1457-5","volume":"69","author":"W Zhao","year":"2013","unstructured":"Zhao W, Maisin A, Baudouin V, et al. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. Eur J Clin Pharmacol. 2013;69(5):1181\u20135.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0396-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0396-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T04:57:55Z","timestamp":1718513875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0396-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,2]]},"references-count":108,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0396-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,2]]}}}